MARKET

ARAV

ARAV

Aravive Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.223
+0.093
+8.19%
Closed 16:00 05/27 EDT
OPEN
1.260
PREV CLOSE
1.130
HIGH
1.260
LOW
1.140
VOLUME
125.98K
TURNOVER
77.30K
52 WEEK HIGH
6.94
52 WEEK LOW
1.020
MARKET CAP
35.24M
P/E (TTM)
-0.5776
1D
5D
1M
3M
1Y
5Y
BRIEF-Aravive Presents Updated Clinical Data At Asco Showing Continued Best-In-Class Potential Of Batiraxcept In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma (Ccrcc)
reuters.com · 2d ago
Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)
Abstract selected for oral discussion on Genitourinary Cancer on Saturday, June 4, 2022Development of biomarker offers the potential of a first in class targeted therapy in renal cancerCompany has a registrational path for potential accelerated approval as...
GlobeNewswire · 2d ago
Aravive to Participate in H.C. Wainwright Global Investment Conference
HOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D, DABT, Chief Executive Officer will present...
GlobeNewswire · 05/17 11:00
We're Keeping An Eye On Aravive's (NASDAQ:ARAV) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Simply Wall St. · 05/16 17:13
Piper Sandler Adjusts Aravive's Price Target to $6 From $9, Reiterates Overweight Rating
MT Newswires · 05/13 05:23
Aravive (ARAV) Reports Q1 Loss, Tops Revenue Estimates
Aravive (ARAV) delivered earnings and revenue surprises of -16.98% and 2.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/12 12:25
Aravive GAAP EPS of -$0.62, revenue of $1.09M
Aravive press release (NASDAQ:ARAV): Q1 GAAP EPS of -$0.62. Revenue of $1.09M (+336.0% Y/Y). As of March 31, 2022, cash and cash equivalents were $65.8 million, compared to $59.4 million
Seekingalpha · 05/12 12:23
Recap: Aravive Q1 Earnings
  Aravive (NASDAQ:ARAV) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/12 12:09
More
No Data
Learn about the latest financial forecast of ARAV. Analyze the recent business situations of Aravive Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ARAV stock price target is 19.00 with a high estimate of 26.00 and a low estimate of 6.00.
High26.00
Average19.00
Low6.00
Current 1.223
EPS
Actual
Estimate
-0.50-0.37-0.25-0.12
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 78
Institutional Holdings: 8.11M
% Owned: 28.15%
Shares Outstanding: 28.83M
TypeInstitutionsShares
Increased
6
65.64K
New
5
1.03M
Decreased
16
346.64K
Sold Out
4
68.61K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Executive Director
Fredric Eshelman
President/Chief Executive Officer/Director
Gail McIntyre
Chief Financial Officer
Vinay Shah
Director
Peter Ho
Director
John Hohneker
Director
Sigurd Kirk
Independent Director
Amato Giaccia
Independent Director
Michael Rogers
Independent Director
Eric Zhang
No Data
No Data
About ARAV
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases including cancer and fibrosis. Its lead product candidate, AVB-500, is an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment and decreased survival. The Company is evaluating AVB-500 in a registrational Phase III trial in platinum resistant ovarian cancer, a Phase Ib/2 trial in second line plus, clear cell renal cell carcinoma (ccRCC), and a Phase Ib/2 trial in first-line treatment of pancreatic adenocarcinoma.

Webull offers kinds of Aravive Inc stock information, including NASDAQ:ARAV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARAV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARAV stock methods without spending real money on the virtual paper trading platform.